Factors influencing treatment decisions in patients with pulmonary arterial hypertension
Abstract
Background: A large proportion of patients with pulmonary arterial hypertension (PAH) is treated with monotherapy although current treatment guidelines emphasize the importance of combination therapies to achieve the treatment goals. Because the reasons for physicians' treatment decisions in routine clinical practice are not well understood, factors influencing these decisions were investigated.
Methods: In this multicentre, non-interventional study, 79 patients who started PAH therapy ≤12 months prior to study inclusion were enrolled. Data available per routine clinical practice were collected. Furthermore, physician's rationale for treatment decision was assessed. All analyses were descriptive.
Results: Patients' mean age was 64 years. Most patients were female (57.0%) with idiopathic PAH (76.0%) and had ≥5 comorbidities (64.6%). At therapy start the significant reasons for choosing combination therapy or monotherapy were patient's risk (81.5%; Odds ratio, OR: 12.38, p=0.0227) and comorbidity status (56.7%; OR: 0.07, p=0.0004), respectively. The proportion of patients receiving combination therapy increased from 45.6% at therapy start to 78.4% at month 24. Concomitantly, the percentage of low-risk patients increased from 14.5% to 35.1%. A significant greater percentage of patients on initial combination therapy achieved an improvement of World Health Organization functional class (85.2% and 50.0%, respectively; OR: 5.75, p=0.0357) between therapy start and end of…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.